GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

AbClon 174900.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

17,240

+5.70%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About AbClon

Its shares trade on KOSDAQ under the ticker 174900.KQ. It has been listed since 18 September 2017. In the fiscal year to 31 December 2025, it reported revenue of ₩4.71bn and a net loss of ₩17.91bn. At that date it held total assets of ₩70.75bn and shareholders' equity of ₩60.44bn.

AbClon, Inc. engages in the development, manufacture and sale of antibody drugs. The company is headquartered in Seoul, Seoul. The company went IPO on 2017-09-18. The firm developed a bio synergy antibody, a therapeutic antibody for a new mechanism that is different from conventional therapeutic agents, and is based on the YPLUS and AffiMab platforms. The firm's products include AC101, AC103, AC104, AC106, AC203, AM201, AM101, AM102 and AM103. The firm distributes its products within domestic market and to overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
18 Sept 2017
Employees
58

Leadership

Pay as last reported

  • Mr. Jong Seo LeeChief Executive Officer, Director
  • Mr. Jun Ho ChoiChief Financial Officer, Managing Director
  • Mr. Jong Hun KimChief Technology Officer, Managing Director
  • Mr. Yong Jun LeeAssistant Managing Director
  • Mr. Hui Su LeeInternal Auditor
  • Mr. Yun LeeAssistant Managing Director
  • Mr. Jeong Ho KimNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • AbClon's YPLUS and AffiMab platforms enable unique antibody drug development.
  • AC101 and AC103 are key products in the domestic market distribution.
  • The firm's 58 employees support focused biotechnology innovation.

Weaknesses

  • Limited employee count of 58 may hinder large-scale production capabilities.
  • Dependence on domestic market for product distribution limits global reach.
  • IPO in 2017 may indicate early-stage financial constraints.

Opportunities

  • Expanding AC106 and AM201 to overseas markets could increase revenue.
  • Growth in biotechnology sector offers new development opportunities.
  • The YPLUS platform can be leveraged for additional therapeutic applications.

Threats

  • Competition from established biotechnology firms in Korea.
  • Regulatory challenges in overseas market entry for antibody drugs.
  • Potential market saturation in the domestic biotechnology sector.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.